Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 9/20 | 0.61 |
| ▸ | MEN1 | O00255 | 8/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | THRA | P10827 | 1/20 | 0.57 |
| ▸ | MMP9 | P14780 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4828294 | 0.92 | CASP3 (0.59) | KMT2AMEN1ALDH1A1GAATHRA | |
| SCHEMBL7669251 | 0.85 | MMP9 (0.76) | KMT2AMEN1HPGDMMP9LMNA | |
| SCHEMBL7669603 | 0.85 | MMP9 (0.76) | KMT2AMEN1HPGDMMP9LMNA | |
| SCHEMBL4828175 | 0.84 | MMP9 (0.59) | KMT2AMEN1MMP9LMNA | |
| SCHEMBL4825269 | 0.82 | MEN1 (0.68) | KMT2AMEN1ALDH1A1GAAHPGD | |
| SCHEMBL7099900 | 0.80 | SLC1A3 (0.59) | ALDH1A1L3MBTL1MMP9 | |
| SCHEMBL7663345 | 0.78 | ITGB3 (0.69) | KMT2AMEN1MMP9 | |
| SCHEMBL4830132 | 0.77 | MMP9 (0.66) | KMT2AMEN1GAAMMP9POLB | |
| SCHEMBL299879 | 0.76 | KMT2A (0.88) | KMT2AMEN1ALDH1A1THRAPOLB | |
| SCHEMBL30868371 | 0.76 | KMT2A (0.88) | KMT2AMEN1ALDH1A1THRAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6403644-B1 | FOR PREVENTION AND/OR TREATMENT OF DISEASES INDUCED BY OVEREXPRESSION AND EXCESS ACTIVITY OF MATRIX METALLOPROTEINASE; FOR EXAMPLE, RHEUMATOID, ARTHROSTEITIS, UNUSUAL BONE RESORPTION, OSTEOPOROSIS, PERIODONTITIS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-06-11 | — | — | US | claimed |
| EP-0757037-A2 | Sulfonylamino acid derivatives as metalloproteinase inhibitors | ONO PHARMACEUTICAL CO., LTD. (JP) | 1997-02-05 | — | — | EP | claimed |
| US-7335686-B2 | Method and composition for treating osteoporosis | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2008-02-26 | — | — | US | disclosed |
| EP-1678124-A1 | NOVEL MOLECULES TO DEVELOP DRUG FOR THE TREATMENT OF OSTEOPOROSIS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005037774-A1 | NOVEL MOLECULES TO DEVELOP DRUG FOR THE TREATMENT OF OSTEOPOROSIS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2005-04-28 | — | — | WO | disclosed |
| US-20050085537-A1 | Method and composition for treating osteoporosis | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2005-04-21 | — | — | US | disclosed |
| US-6403644-B1 | FOR PREVENTION AND/OR TREATMENT OF DISEASES INDUCED BY OVEREXPRESSION AND EXCESS ACTIVITY OF MATRIX METALLOPROTEINASE; FOR EXAMPLE, RHEUMATOID, ARTHROSTEITIS, UNUSUAL BONE RESORPTION, OSTEOPOROSIS, PERIODONTITIS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-06-11 | — | — | US | disclosed |
| US-6177466-B1 | Sulfonylamino acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-01-23 | — | — | US | disclosed |
| EP-0757037-A2 | Sulfonylamino acid derivatives as metalloproteinase inhibitors | ONO PHARMACEUTICAL CO., LTD. (JP) | 1997-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085537-A1 | Method and composition for treating osteoporosis | SOST, CALCR, MSR1 | KMT2A 1340/4885MEN1 3066/4885ALDH1A1 4713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.